330784-47-9 | Avanafil

Packsize	Purity	Availability	Price	Discounted Price
250mg	95%	in stock	$23.00	$16.00
1g	95%	in stock	$43.00	$30.00
25g	95%	in stock	$785.00	$549.00

Description

• Catalog Number: AB45574
• Chemical Name: Avanafil
• CAS Number: 330784-47-9
• Molecular Formula: C23H26ClN7O3
• Molecular Weight: 483.9506
• MDL Number: MFCD11977961
• SMILES: OC[C@@H]1CCCN1c1ncc(c(n1)NCc1ccc(c(c1)Cl)OC)C(=O)NCc1ncccn1

Computed Properties

• Complexity: 642
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 9
• XLogP3: 2.6

Literature

• An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.

  Expert opinion on pharmacotherapy 20130701

• Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.

  Therapeutic advances in urology 20130201

• Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.

  Mayo Clinic proceedings 20120901

• Re: Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.

  The Journal of urology 20120901

• Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.

  The Journal of urology 20120801

• Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature.

  The journal of spinal cord medicine 20120701

• FDA approves new ED remedy.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120601

• A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.

  The journal of sexual medicine 20120401

• Avanafil for the treatment of erectile dysfunction.

  Drugs of today (Barcelona, Spain : 1998) 20120101

• Avanafil for treatment of erectile dysfunction: review of its potential.

  Vascular health and risk management 20120101

• cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.

  Current neuropharmacology 20111201

• Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010).

  Expert opinion on therapeutic patents 20111001

• Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

  British journal of clinical pharmacology 20110801

• Future prospects in the treatment of erectile dysfunction: focus on avanafil.

  Drug design, development and therapy 20110101

• Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.

  Expert opinion on investigational drugs 20101101

• Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.

  Clinical therapeutics 20100601

• Diagnosis and treatment of erectile dysfunction--a practical update.

  Journal of medicine and life 20091115

• Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

  Psychopharmacology 20090101

• Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress.

  Expert opinion on investigational drugs 20080601

• Looking to the future for erectile dysfunction therapies.

  Drugs 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20061201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20061001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040101